Abstract
Background and Aims: Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI).
Methods: A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined.
Results: There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p < 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p < 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p < 0.001) but negatively correlated with the Trail Making Test-B (r = −0.413; p < 0.001), fasting blood-glucose (r = −0.372; p < 0.001), glycosylated hemoglobin (r = −0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = −0.560; p < 0.001) and the mean amplitude of glycemic excursions (r = −0.551; p < 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels.
Conclusion: This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.
Keywords: Homeostasis model of assessment for insulin resistance, insulin degrading enzyme, mild cognitive impairment, the mean amplitude of glycemic excursions, the Trail Making Test-B, Type 2 diabetes.
Current Alzheimer Research
Title:Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Volume: 13 Issue: 12
Author(s): Jie Sun, Wenqing Xia, Rongrong Cai, Pin Wang, Rong Huang, Haixia Sun, Sai Tian, Xue Dong and Shaohua Wang
Affiliation:
Keywords: Homeostasis model of assessment for insulin resistance, insulin degrading enzyme, mild cognitive impairment, the mean amplitude of glycemic excursions, the Trail Making Test-B, Type 2 diabetes.
Abstract: Background and Aims: Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI).
Methods: A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined.
Results: There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p < 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p < 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p < 0.001) but negatively correlated with the Trail Making Test-B (r = −0.413; p < 0.001), fasting blood-glucose (r = −0.372; p < 0.001), glycosylated hemoglobin (r = −0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = −0.560; p < 0.001) and the mean amplitude of glycemic excursions (r = −0.551; p < 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels.
Conclusion: This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.
Export Options
About this article
Cite this article as:
Sun Jie, Xia Wenqing, Cai Rongrong, Wang Pin, Huang Rong, Sun Haixia, Tian Sai, Dong Xue and Wang Shaohua, Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160615091043
DOI https://dx.doi.org/10.2174/1567205013666160615091043 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Double-edged Role of K<sub>Na</sub> Channels in Brain Tuning: Identifying Epileptogenic
Network Micro-Macro Disconnection
Current Neuropharmacology Rufinamide Improves Functional and Behavioral Deficits <i>via</i> Blockade of Tetrodotoxin-Resistant Sodium Channels in Diabetic Neuropathy
Current Neurovascular Research Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Valproate and Neuroendocrine Changes in Relation to Women Treated for Epilepsy and Bipolar Disorder: A Review
Current Medicinal Chemistry Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?
Current Medical Imaging A Review on Possible Therapeutic Effect of Nigella sativa and Thymoquinone in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Clinical Improvement and Cortical Adaptations After Functional Electrical Stimulation in Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Topiramate Decelerates Bicarbonate-Driven Acid-Elimination of Human Neocortical Neurons: Strategic Significance for its Antiepileptic, Antimigraine and Neuroprotective Properties
CNS & Neurological Disorders - Drug Targets Nicotinic Receptors in Neurodegeneration
Current Neuropharmacology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design The Management and Alternative Therapies for Comorbid Sleep Disorders in Epilepsy
Current Neuropharmacology T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry